Moderna on Friday beat third-quarter revenue and earnings estimates and raised its full-year outlook, now calling for 2026 revenue growth of 15% to 25%, up from its earlier guidance of up to 10%. Shares rose roughly 3% in premarket trading. Those are good numbers, and they deserve to be taken seriously rather than dismissed as spin.

Revenue jumped 29% to $1.31 billion, and the company posted net income of $162 million, or 38 cents per share, compared with a net loss of $200 million a year earlier. CEO Stéphane Bancel credited new products and geographic diversification, citing Canada, the U.K. and Asia, and said lower costs helped push the company into profit. Some of that is encouraging. A company that expands its customer base and trims spending is doing what it should.

Yet the report also shows how much of the story still rests on expectations. Bancel said the next-generation Covid vaccine had only a "small launch" last year and that the new stand-alone flu shot will have a "limited launch" in 2026. In other words, a meaningful part of the growth outlook depends on products whose commercial track record is still short. Covid revenue is seasonal, and contract timing matters. Investors should ask how much of the raised guidance reflects durable demand and how much reflects the timing of contracts and deliveries.

The cancer vaccine data, which Bancel described as drawing a "surprising reaction" after leaked results hit social media, is another reminder that the market is pricing future promise. Moderna's stock has climbed more than 700% this year, largely on optimism about that shot. Enthusiasm from physicians who said they hope to use the data is a positive sign, but it is not the same as approval or proven commercial success.

My view is simple. Moderna should keep reporting results in this detail and should be measured about what it promises. Investors should reward the quarter they can see while demanding clear, verifiable milestones for the rest. A stock that has multiplied several times over in one year needs fundamentals to catch up, and this report, strong as it is, shows only part of that work.